We found that the expression of TIGIT, which inhibits NK cell function, is increased on CD56+ and CD56dim NK cells in DN-CML PB compared with those in healthy individuals (HIs), and it is restored to normal in patients who achieve MR. This evidence concerns the gene TIGIT and chronic myelogenous leukemia, BCR-ABL1 positive.